Category: Cure

Diapep277 - logo

DiaPep277 Granted Orphan Drug Designation by FDA

The U.S. FDA has granted Orphan Drug designation for DiaPep277 for the treatment of type 1 diabetes (T1D) patients with residual beta cell function. The designation of Orphan Drug status offers 7 years marketing exclusivity from the time of approval....
0 Shares
Diapep277

Positive Results for DiaPep277 Type 1 Diabetes Treatment in Phase 3 Study

Andromeda Biotech has announced positive initial results from a pivotal phase III clinical study of type 1 diabetes treatment, DiaPep227. The 24-month randomized, placebo-controlled study was designed to assess the safety and efficacy of DiaPep277, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with type 1 diabetes...
0 Shares
TedXDelMar Logo

TEDx Ticket Giveaway!

The top names in diabetes research will be at TEDxDelMar in San Diego, discussing the future of diabetes care and cure. Want to be there? ASweetLife, in conjunction with the organizing committee of the event, is giving away 10 free tickets to TEDxDelMar! So if you can be in San Diego on October 15, 2011 and would like to attend, send an email to TEDx@asweetlife.org, and we'll enter you in a drawing.
0 Shares
Diamyd_logo

Diamyd Shifts Away from Diabetes To Cut Costs

Diamyd Medical announced it has shifted its focus from the development of the diabetes therapy Diamyd® to the the development of drug candidates for the treatment of chronic pain....
0 Shares
Diamyd_logo

Diamyd Terminates US Phase III Study, DiaPrevent

Diamyd Medical has suspended dosing in its US Phase III study, DiaPrevent, with the antigen-based therapy Diamyd® following consultation with the US Food and Drug Administration (FDA). Termination follows a blinded review of the efficacy data collected to date in the study as well as the previously reported negative outcome...
0 Shares